

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Evaluation of the effect of Dual FSH/HCG triggering on the success rate of IUI in couples diagnosed with unexplained infertility
Evaluation of the effect of Dual Follicle Stimulating Hormone(FSH)/Human Chorionic Gonadotropin hormone(HCG) triggering on the success rate of Intrauterine insemination (IUI) in couples diagnosed with unexplained infertility.

Protocol summary

Study aim

Evaluation of the effect of Dual Follicle Stimulating Hormone(FSH)/Human Chorionic Gonadotropin hormone(HCG) triggering on the success rate of Intrauterine insemination (IUI) in couples diagnosed with unexplained infertility.

Design

Clinical trial with control group. The number of samples will be 80 (40 patients in each group). They will be divided randomly into intervention and control groups. This study is Single blind.

Settings and conduct

This study will be conducted in Al-Zahra Hospital, Tabriz, on women whose cause of infertility is unknown. The patients will be divided randomly into intervention and control groups. In the control group, two ampoules of human chorionic gonadotropin (HCG) 5000 units will be injected intramuscularly. And in the intervention group, two ampoules of HCG (5000 units intramuscular) and 150 units of follicle stimulating hormone (r-FSH) will be injected subcutaneously. In both groups, 34 to 36 hours later, intrauterine sperm insemination (IUI) will be performed as usual.

Participants/Inclusion and exclusion criteria

women between the ages of 20 and 38 who are candidates for of Intrauterine insemination will be included and will be prohibited from participating in the study if they have an underlying disease.

Intervention groups

in Control group, two ampoules of human chorionic gonadotropin hormone 5000 intramuscular units will be injected intramuscularly. And In Intervention group, two ampoules of HCG 5000 intramuscular units, along with

150 units of follicle stimulating hormone, are also received subcutaneously. In both groups 34 to 36 hours later, Intrauterine insemination is performed as usual.

Main outcome variables

The success rate in clinical pregnancy is considered as the main outcome of this study.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220702055335N2**

Registration date: **2022-09-06, 1401/06/15**

Registration timing: **registered_while_recruiting**

Last update: **2022-09-06, 1401/06/15**

Update count: **0**

Registration date

2022-09-06, 1401/06/15

Registrant information

Name

Parvin Hakimi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3553 9161

Email address

parvin.hakimi56@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-08-27, 1401/06/05

Expected recruitment end date

2023-08-27, 1402/06/05

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of Dual FSH/HCG triggering on the success rate of IUI in couples diagnosed with unexplained infertility Evaluation of the effect of Dual Follicle Stimulating Hormone(FSH)/Human Chorionic Gonadotropin hormone(HCG) triggering on the success rate of Intrauterine insemination (IUI) in couples diagnosed with unexplained infertility.

Public title

Evaluation of the effect of Dual Follicle Stimulating Hormone(FSH)/Human Chorionic Gonadotropin hormone(HCG) triggering on the success rate of Intrauterine insemination (IUI) in couples diagnosed with unexplained infertility.

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Having an informed consent to participate in the study
Unexplained infertility diagnosis
The health of the uterus structure
Normal pap smear test
Normal sperm analysis
Women between 20 and 38 years old

Exclusion criteria:

Moderate to severe endometriosis
Hyperprolactinemia
Hyperthyroidism
Hypothyroidism
Ovarian Cysts
Kidney and liver failure
Secondary infertility

Age

From **20 years** old to **38 years** old

Gender

Female

Phase

3

Groups that have been masked

- Outcome assessor
- Data analyser

Sample size

Target sample size: **80**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization and blinding will be done using the RANDOM.ORG website. Thus, for each patient, a number from 1 to 80 will be given. And then, it will be obtained by the relevant site and by entering the range of random numbers. The obtained numbers will be assigned equally to two groups.

Blinding (investigator's opinion)

Single blinded

Blinding description

Patients will be divided randomly into two groups (A and B). The data collection form will be provided to the analyzer with the header A and B without mentioning the type of method performed on the patient. The results of the data analysis, will be provided to the analyst without mentioning the name of the method (group A and B) to examine the consequences. So, these people will be blinded.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee Of Tabriz University Of Medical Sciences

Street address

Third Floor, Central Building of Number2, Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5166616471

Approval date

2022-06-01, 1401/03/11

Ethics committee reference number

IR.TBZMED.REC.1401.235

Health conditions studied**1****Description of health condition studied**

Female infertility

ICD-10 code

N97.9

ICD-10 code description

Female infertility, unspecified

Primary outcomes**1****Description**

Clinical pregnancy rate

Timepoint

28 days after transfer

Method of measurement

Vaginal sonography

Secondary outcomes

1

Description

Chemical pregnancy rate

Timepoint

14 days after transfer

Method of measurement

BhCG test

Intervention groups

1

Description

Intervention group: after checking the state of the ovaries and ensuring the presence of at least one mature follicle larger than 18 mm (between one and five follicles) and a suitable endometrium with a thickness of at least 7 mm, two ampoules of human chorionic gonadotropin hormone(HCG) 5000 intramuscular units (manufactured by Poyesh Pharmaceutical Company Daru, Iran) along with 150 units of (follicle stimulating hormone) FSH (Two ampoules of 75 units of Cinnal F) (manufactured by Shafayab Gostar Company) are also received subcutaneously. 34 to 36 hours later, Intrauterine insemination (IUI) is performed as usual.

Category

Treatment - Drugs

2

Description

Control group: after checking the state of the ovaries and ensuring the presence of at least one mature follicle larger than 18 mm (between one and five follicles) and a suitable endometrium with a thickness of at least 7 mm, two ampoules of human chorionic gonadotropin hormone(HCG) 5000 intramuscular units (manufactured by Poyesh Pharmaceutical Company) Daru, Iran) will be injected intramuscularly. 34 to 36 hours later, Intrauterine insemination (IUI) is performed as usual.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Alzahra Hospital

Full name of responsible person

Dr.Parvin Hakimi

Street address

Alzahra Hospital, South Artesh St.,Tabriz, iran

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 41 3553 9161

Email

lahroudin@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for Research,Tabriz University Of Medical Sciences

Full name of responsible person

Dr.Parviz Shahabi

Street address

No. 2 Central Building, Tabriz University of Medical Sciences, Goltasht Street, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 41 3335 7310

Email

research-vice@tbzmed.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for Research,Tabriz University Of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Dr.Parvin Hakimi

Position

Assistant Professor Professor of Obstetrics
Gynecology

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Tabriz University Of Medical Sciences, Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 35519161

Email

lahroudin@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Dr.Parvin Hakimi

Position

Assistant Professor Professor of Obstetrics
Gynecology

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Tabriz University Of Medical Sciences, Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 35519161

Email

lahroudin@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Dr.Parvin Hakimi

Position

Assistant Professor Professor of Obstetrics
Gynecology

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Tabriz University Of Medical Sciences, Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 35519161

Email

lahroudin@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available